Idera Pharmaceuticals (IDRA) & Prana Biotechnology (PRAN) Head-To-Head Contrast
Idera Pharmaceuticals (NASDAQ: IDRA) and Prana Biotechnology (NASDAQ:PRAN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.
Earnings and Valuation
This table compares Idera Pharmaceuticals and Prana Biotechnology’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Idera Pharmaceuticals||$16.17 million||25.63||-$42.73 million||($0.33)||-8.39|
|Prana Biotechnology||$2.54 million||1.56||-$5.52 million||N/A||N/A|
Prana Biotechnology has higher revenue, but lower earnings than Idera Pharmaceuticals.
This table compares Idera Pharmaceuticals and Prana Biotechnology’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
Idera Pharmaceuticals has a beta of 2.23, suggesting that its share price is 123% more volatile than the S&P 500. Comparatively, Prana Biotechnology has a beta of -0.26, suggesting that its share price is 126% less volatile than the S&P 500.
Institutional & Insider Ownership
30.9% of Idera Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.8% of Prana Biotechnology shares are owned by institutional investors. 30.3% of Idera Pharmaceuticals shares are owned by company insiders. Comparatively, 38.8% of Prana Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This is a breakdown of recent ratings for Idera Pharmaceuticals and Prana Biotechnology, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Idera Pharmaceuticals presently has a consensus price target of $5.75, suggesting a potential upside of 107.58%. Given Idera Pharmaceuticals’ higher probable upside, equities analysts plainly believe Idera Pharmaceuticals is more favorable than Prana Biotechnology.
Idera Pharmaceuticals beats Prana Biotechnology on 6 of the 11 factors compared between the two stocks.
About Idera Pharmaceuticals
Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company’s drug candidates include IMO-8400, IMO-2125 and IMO-9200. The Company has designed TLR antagonists and agonists to act by modulating the activity of targeted TLRs. It is developing its 3GA technology to turn off the mRNA associated with disease causing genes.
About Prana Biotechnology
Prana Biotechnology Limited is a development-stage medical biotechnology company. The Company is engaged in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer’s disease, Huntington disease, Parkinson’s disease and other neurological disorders. The Company’s lead product candidates are PBT2 and PBT434. The Company’s lead drug candidate PBT2 is being developed for the treatment of Alzheimer’s and Huntington’s diseases. The Company also has advanced a drug candidate for Parkinson’s disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in pre-clinical toxicology testing. Its other applications for its therapies include certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease (the human variant of Mad Cow disease), and a range of orphan neurodegenerative disorders.
Receive News & Ratings for Idera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.